HCW Biologics (NASDAQ:HCWB) SVP Lee Flowers Purchases 7,736 Shares

HCW Biologics Inc. (NASDAQ:HCWB) SVP Lee Flowers bought 7,736 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was purchased at an average cost of $2.58 per share, for a total transaction of $19,958.88. Following the completion of the acquisition, the senior vice president owned 8,691 shares in the company, valued at approximately $22,422.78. This trade represents a 810.05% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

HCW Biologics Stock Performance

Shares of HCW Biologics stock traded up $0.05 on Friday, reaching $3.20. 61,185 shares of the stock were exchanged, compared to its average volume of 1,508,655. The firm’s 50 day moving average is $6.78 and its 200-day moving average is $5.21. HCW Biologics Inc. has a one year low of $1.50 and a one year high of $44.10. The firm has a market cap of $5.11 million, a PE ratio of -0.06 and a beta of 2.29.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.64) by $3.01. The business had revenue of $6.54 million for the quarter, compared to analyst estimates of $6.54 million. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HCWB. Maxim Group boosted their price target on HCW Biologics from $12.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research report on Friday, July 17th. Finally, Wall Street Zen raised HCW Biologics to a “hold” rating in a research note on Saturday, May 23rd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, HCW Biologics has a consensus rating of “Hold” and an average target price of $30.00.

Institutional Trading of HCW Biologics

A hedge fund recently bought a new position in HCW Biologics stock. Armistice Capital LLC bought a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics as of its most recent filing with the Securities & Exchange Commission. 2.96% of the stock is owned by hedge funds and other institutional investors.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.